Eagle Pharmaceuticals, Inc.
EGRX
$1.90
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -2.50% | 9.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.50% | 9.24% | |||
| Cost of Revenue | -2.55% | -12.92% | |||
| Gross Profit | -2.48% | 20.01% | |||
| SG&A Expenses | -1.11% | 10.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.35% | 4.20% | |||
| Operating Income | -12.48% | 40.72% | |||
| Income Before Tax | -9.12% | -23.10% | |||
| Income Tax Expenses | -7.74% | -12.80% | |||
| Earnings from Continuing Operations | -10.19% | -29.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.19% | -29.58% | |||
| EBIT | -12.48% | 40.72% | |||
| EBITDA | -8.36% | 23.84% | |||
| EPS Basic | -10.40% | -29.81% | |||
| Normalized Basic EPS | -14.64% | -26.52% | |||
| EPS Diluted | -11.36% | -28.97% | |||
| Normalized Diluted EPS | -14.45% | -26.44% | |||
| Average Basic Shares Outstanding | 0.24% | 0.33% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||